Abstract | WHAT IS KNOWN AND OBJECTIVE: CASE SUMMARY: WHAT IS NEW AND CONCLUSION:
|
Authors | Lijiao Xie, Yongdong Feng, Jianguo Sun |
Journal | Journal of clinical pharmacy and therapeutics
(J Clin Pharm Ther)
Vol. 47
Issue 2
Pg. 248-250
(Feb 2022)
ISSN: 1365-2710 [Electronic] England |
PMID | 34240438
(Publication Type: Case Reports)
|
Copyright | © 2021 John Wiley & Sons Ltd. |
Chemical References |
- Acrylamides
- Aniline Compounds
- Antineoplastic Agents
- Indoles
- Protein Kinase Inhibitors
- Quinolines
- anlotinib
- osimertinib
- ErbB Receptors
|
Topics |
- Acrylamides
(adverse effects, therapeutic use)
- Adenocarcinoma of Lung
(drug therapy)
- Aniline Compounds
(adverse effects, therapeutic use)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Dermatoglyphics
- ErbB Receptors
(antagonists & inhibitors)
- Humans
- Indoles
(adverse effects, therapeutic use)
- Lung Neoplasms
(drug therapy)
- Male
- Middle Aged
- Protein Kinase Inhibitors
(therapeutic use)
- Quinolines
(adverse effects, therapeutic use)
|